Home / Deep Research / Postcricoid Region Cancer

Postcricoid Region Cancer

Postcricoid Region Cancer (Postcricoid Hypopharyngeal Carcinoma): Disease Characteristics Research Report

2026-05-10
Falcon MONDO:0004635 Model: Edison Scientific Literature 37 citations

Postcricoid Region Cancer (Postcricoid Hypopharyngeal Carcinoma): Disease Characteristics Research Report

Target disease

Disease name: Postcricoid region cancer (most commonly postcricoid hypopharyngeal squamous cell carcinoma, a hypopharyngeal cancer subsite) (glastonbury2020headandneck pages 1-2, mousavi2024globalepidemiologyand pages 1-2).

Executive summary (current understanding)

Postcricoid region cancer is best conceptualized as a hypopharyngeal malignancy arising from the postcricoid region (anterior wall of the hypopharynx, overlying the posterior cricoid cartilage), most often squamous cell carcinoma (SCC). It is clinically important because (i) it is frequently advanced at diagnosis, (ii) it exhibits submucosal spread toward the cervical esophagus, and (iii) treatment requires balancing oncologic control with laryngo-esophageal function preservation (glastonbury2020headandneck pages 1-2, sahu2023imagingrecommendationsfor pages 5-8, katano2024earlystagehypopharyngealsquamous pages 1-2).

A concise evidence table of key recent quantitative findings is provided below.

Table (click to expand)
Topic Key quantitative data Key qualitative takeaway Source (first author, year) URL
Global epidemiology of hypopharyngeal cancer (includes postcricoid subsite) 84,254 new cases globally in 2020; ASIR 0.91/100,000; 38,599 deaths; ASMR 0.41/100,000; MIR 0.45; projected increase by 2040: new cases +50%, deaths +55%; subsite distribution: ~70% pyriform sinus, ~25% posterior pharyngeal wall, remainder largely post-cricoid; HC is <5% of head and neck malignancies (mousavi2024globalepidemiologyand pages 1-2, mousavi2024globalepidemiologyand pages 2-3) Postcricoid-region cancer is best understood as a rare hypopharyngeal cancer subsite within a high-mortality disease that is more common in men and often diagnosed late. Mousavi, 2024 https://doi.org/10.3389/fonc.2024.1398063
Symptoms and NCCN diagnostic workup Common symptoms: hoarseness, breathing difficulty, dysphagia/odynophagia, foreign-body sensation, ear ache; advanced signs include stridor/aspiration. NCCN-referenced workup: examination under anesthesia with endoscopy/biopsy; CECT and/or MRI of primary and neck; chest CT for advanced nodal disease/smokers; FDG PET-CT for stage III-IV disease (sahu2023imagingrecommendationsfor pages 1-2, sahu2023imagingrecommendationsfor pages 5-8, sahu2023imagingrecommendationsfor pages 2-3) Endoscopy is essential for mucosal assessment and biopsy, but CT/MRI/PET are required to define submucosal spread, cartilage invasion, nodal disease, response, and recurrence in postcricoid tumors. Sahu, 2023 https://doi.org/10.1055/s-0042-1759504
Radical radiotherapy outcomes for early-stage HSCC, including postcricoid subsite Uniform RT: 70 Gy in 35 fractions to primary site plus elective nodal irradiation; 5-year OS 80.7% (95% CI 66.5-89.4%); 5-year DFS 66.4%; 5-year LRC 79.3%; postcricoid subsite 5-year OS 100% in this small series; no grade >=3 toxicities reported (katano2024earlystagehypopharyngealsquamous pages 1-2, katano2024earlystagehypopharyngealsquamous pages 2-5) For stage I-II hypopharyngeal SCC, organ-preserving radical RT can produce strong long-term control with favorable toxicity; postcricoid outcomes were encouraging but based on very small numbers. Katano, 2024 https://doi.org/10.1007/s00405-024-08722-w
Surgery-based therapy vs definitive chemoradiotherapy in hypopharyngeal carcinoma 167 patients; 5-year OS 59.7% with surgery-based therapy vs 24.0% with definitive CRT (p<0.0001); 5-year PFS 49.9% vs 22.6% (p=0.0002); surgery also improved LFFS, RFFS, DMFFS; survival similar between modalities mainly for T3 or stage III disease (lin2023survivalanalysesof pages 1-2, lin2023survivalanalysesof pages 2-3) In retrospective data, surgery-based therapy often outperformed definitive CRT overall, but organ-preservation approaches may remain reasonable for selected T3/stage III cases. Extensive postcricoid/esophageal inlet involvement favored total laryngectomy/pharyngectomy. Lin, 2023 https://doi.org/10.3389/fonc.2023.1109417
Plummer-Vinson syndrome (PVS) as a risk context for postcricoid/pharyngeal SCC Reported malignancy incidence in PVS: 3-15% overall; one report cites post-cricoid carcinoma in ~4-16% across studies; yearly surveillance endoscopy is commonly suggested though no definitive guideline exists (patil2023endoscopicsubmucosaldissection pages 1-2, lo2019plummervinsonsyndromeimproving pages 5-6, patil2023endoscopicsubmucosaldissection pages 2-4, lo2019plummervinsonsyndromeimproving pages 2-3) PVS (iron deficiency anemia + dysphagia + upper esophageal/post-cricoid web) is a classic premalignant association for postcricoid/pharyngeal SCC; long-term surveillance is generally recommended despite limited evidence and lack of standardized intervals. Lo, 2019; Patil, 2023 https://doi.org/10.2147/JMDH.S180410 ; https://doi.org/10.1055/s-0042-1759510
Organ-preservation chemoimmunotherapy studies/trials NCT04156698: phase II, n=51, camrelizumab + modified TPF; ORR 82.4% (42/51); 2-year OS 83.0%; 2-year PFS 77.1%; 2-year larynx preservation rate 70.0%. NCT06039631: randomized phase II, planned n=82; neoadjuvant chemoimmunotherapy followed by organ-preservation surgery vs concurrent chemoradiation; RT arm 70 Gy/35 fractions + weekly cisplatin; primary endpoint 2-year PFS; key secondary endpoints include larynx preservation, OS, QoL (NCT04156698 chunk 1, NCT06039631 chunk 1) Recent organ-preservation strategies are shifting toward PD-1-based chemoimmunotherapy for locally advanced hypopharyngeal/laryngeal cancer, aiming to improve response and preserve laryngeal function without routine upfront total laryngectomy. Gong/Wang, 2024-2023 (NCT04156698/NCT06039631) https://clinicaltrials.gov/study/NCT04156698 ; https://clinicaltrials.gov/study/NCT06039631

Table: This table summarizes key recent evidence and quantitative findings relevant to postcricoid-region cancer within hypopharyngeal squamous cell carcinoma. It highlights epidemiology, diagnosis, outcomes, risk context, and emerging organ-preservation approaches.

1. Disease information

1.1 Disease overview and definition

1.2 Key identifiers and ontology mappings

  • ICD-O-3 topography (commonly used in SEER/registry datasets): C13.0 = postcricoid region ().
  • MONDO: OpenTargets returns MONDO_0021358 (neoplasm of hypopharynx) as a related disease entity in its hypopharynx cancer space (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma). A postcricoid-specific MONDO term was not retrieved in the current evidence set.
  • EFO terms observed via OpenTargets context: hypopharyngeal carcinoma EFO_0002938; hypopharyngeal squamous cell carcinoma EFO_1001960 (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma).

1.3 Common synonyms

1.4 Evidence source type

The evidence here is largely from aggregated disease-level resources (GLOBOCAN 2020 analysis, imaging recommendations, trials) and cohort studies/case series, not single EHR-derived patient observations (mousavi2024globalepidemiologyand pages 1-2, sahu2023imagingrecommendationsfor pages 1-2, katano2024earlystagehypopharyngealsquamous pages 1-2).

2. Etiology

2.1 Causal factors and mechanisms (high-level)

Most postcricoid cancers are mucosal epithelial SCCs arising in the upper aerodigestive tract, consistent with the broader hypopharyngeal SCC pathogenesis (mousavi2024globalepidemiologyand pages 1-2, li2026novellaryngealpreservation pages 1-2).

2.2 Risk factors

Lifestyle/environmental: * Tobacco and alcohol are highlighted as major risk factors in imaging-based clinical guidance for larynx/hypopharynx cancers (sahu2023imagingrecommendationsfor pages 1-2).

Syndromic/premalignant association (important for the postcricoid region): Plummer–Vinson syndrome (PVS) * PVS is classically defined by the triad of iron deficiency anemia, post-cricoid dysphagia, and an upper esophageal/post-cricoid web, and is consistently described as associated with upper aerodigestive squamous cancers (patil2023endoscopicsubmucosaldissection pages 1-2, lo2019plummervinsonsyndromeimproving pages 1-2). * Quantitative risk ranges reported in retrieved sources: * “Malignancies occur at an incidence of 3–15%” in PVS (lo2019plummervinsonsyndromeimproving pages 2-3). * A pooled frequency range reported in one PVS-focused source indicates post-cricoid carcinoma occurs in ~4–16% across studies (patil2023endoscopicsubmucosaldissection pages 1-2).

Protective factors: not clearly identified in the retrieved evidence set for this specific subsite.

2.3 Gene–environment considerations

The strongest evidence in this set supports classic carcinogen exposure (tobacco/alcohol) and mucosal vulnerability due to iron deficiency (PVS) as converging pathways toward squamous carcinogenesis (sahu2023imagingrecommendationsfor pages 1-2, patil2023endoscopicsubmucosaldissection pages 2-4).

3. Phenotypes (clinical presentation)

3.1 Key symptoms and signs

Common presenting features for larynx/hypopharynx cancers include hoarseness, breathing difficulty, dysphagia/odynophagia, foreign-body sensation, ear ache, and advanced presentations including stridor or aspiration (sahu2023imagingrecommendationsfor pages 1-2).

Early-stage hypopharyngeal SCC (including postcricoid) is often not detected promptly. One 2024 cohort reports: “HSCC is often undetected until advanced stages” and notes that “More than 50% of patients with hypopharyngeal cancers … present at an advanced stage.” (katano2024earlystagehypopharyngealsquamous pages 1-2).

3.2 Phenotype characteristics

  • Typical onset: adult-onset cancer (registry-level; not a congenital disease entity).
  • Progression: often insidious until advanced.

3.3 Quality-of-life impact

Swallowing and voice/airway issues are intrinsic to hypopharyngeal/postcricoid tumors due to proximity to the larynx and esophageal inlet; contemporary organ-preservation trials explicitly include QoL instruments (e.g., EORTC QLQ-H&N35; MDADI; VHI-10) as endpoints (NCT06957938 chunk 2, NCT06039631 chunk 1).

3.4 Suggested HPO terms (examples)

(These are suggested mappings based on the symptom set described in the clinical literature above; the exact HPO identifiers were not explicitly provided in retrieved sources.)

4. Genetic / molecular information

4.1 Somatic landscape (current understanding; largely extrapolated from HNSCC/HSCC)

Postcricoid cancers are usually SCC and share canonical head-and-neck SCC alterations.

  • A 2024 review emphasizes TP53 as central: “Mutation on the TP53 tumour suppressor gene is a key factor in cancer development” and notes TP53-related biology intersects with tumor immune behavior including PD-L1 (CD274) in some contexts (shirima2024epithelial‑derivedheadand pages 3-4).
  • A 2023 review lists recurrently altered tumor suppressors and oncogenes in HNSCC, including TP53, CDKN2A, NOTCH1, FAT1, EGFR, PIK3CA, and RAS/HRAS (afshari2023potentialalternativetherapeutic pages 1-2).
  • OpenTargets associations (supportive, not definitive for this subsite) link hypopharyngeal carcinoma space to targets including ADH1B (with PubMed-listed evidence) and, in related pharyngeal SCC entities, to TP53, EGFR, MET, PIK3CA, NOTCH1, KMT2D/KMT2C, etc. (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma).

4.2 Key pathways/processes implicated

From the retrieved HNSCC-focused reviews, major implicated signaling and cellular processes include: * Cell-cycle dysregulation / DNA damage response (TP53, CDKN2A/p16, RB1/CCND1 context) (shirima2024epithelial‑derivedheadand pages 3-4, afshari2023potentialalternativetherapeutic pages 1-2). * RTK/RAS and EGFR signaling (EGFR and RAS family contributions, therapeutic implications such as cetuximab resistance) (shirima2024epithelial‑derivedheadand pages 3-4). * PI3K/AKT/mTOR pathway and PTEN (shirima2024epithelial‑derivedheadand pages 3-4). * Squamous differentiation programs including NOTCH signaling (afshari2023potentialalternativetherapeutic pages 1-2). * Immune evasion/checkpoint biology (PD-1/PD-L1 axis relevance in SCC immunotherapy selection) (shirima2024epithelial‑derivedheadand pages 3-4).

4.3 Suggested GO terms (examples)

(These are suggested mechanism mappings; explicit GO annotations were not provided in the retrieved sources.)

4.4 Suggested Cell Ontology terms (examples)

(Again, suggested mappings; CL identifiers are not explicitly stated in retrieved sources.)

5. Environmental information

5.1 Environmental/lifestyle factors

5.2 Infectious agents

HPV appears to be relevant to a subset of non-oropharyngeal SCCs, but postcricoid-specific HPV prevalence was not extracted from the current evidence set.

6. Mechanism / pathophysiology

6.1 Causal chain (subsite-relevant, evidence-based narrative)

  1. Chronic exposures/host susceptibility (tobacco/alcohol carcinogens; iron deficiency and mucosal degeneration in PVS) predispose to squamous mucosal dysplasia and malignant transformation (sahu2023imagingrecommendationsfor pages 1-2, patil2023endoscopicsubmucosaldissection pages 2-4).
  2. Tumor arises in a region with propensity for submucosal spread; imaging guidance notes postcricoid hypopharyngeal carcinoma can show submucosal spread toward the cervical esophagus, and MRI can better delineate extent (sahu2023imagingrecommendationsfor pages 5-8).
  3. Progressive local growth leads to dysphagia and airway/voice symptoms, while deep spread and nodal metastasis drive advanced-stage presentation (sahu2023imagingrecommendationsfor pages 1-2, katano2024earlystagehypopharyngealsquamous pages 1-2).

6.2 Immune system involvement (current understanding)

The broader HNSCC literature emphasizes immune checkpoint biology (PD-1/PD-L1) as both a therapeutic target and part of immune evasion programs. TP53 alterations may intersect with immune-related tumor behaviors, and immune checkpoint inhibition is central in contemporary organ-preservation trials for hypopharyngeal cancer (shirima2024epithelial‑derivedheadand pages 3-4, NCT04156698 chunk 1).

7. Anatomical structures affected

7.1 Organ/tissue localization

7.2 Suggested UBERON terms (examples)

(UBERON IDs are provided as suggested ontology mappings; explicit UBERON annotations were not contained in the retrieved text.)

7.3 Visual evidence for anatomy and subsite imaging

The Sahu 2023 imaging recommendations include CT figures of normal hypopharynx anatomy and imaging of postcricoid-region cancer, as well as TNM staging tables, supporting subsite localization and staging criteria (sahu2023imagingrecommendationsfor media 624946c3, sahu2023imagingrecommendationsfor media dd0e55cc, sahu2023imagingrecommendationsfor media 9d694104, sahu2023imagingrecommendationsfor media 0adf3cdb, sahu2023imagingrecommendationsfor media ea5671f7, sahu2023imagingrecommendationsfor media 2fc9a3ce).

8. Temporal development

8.1 Onset and progression

Hypopharyngeal SCC commonly presents late; early disease may be subtle. In the 2024 early-stage HSCC radiotherapy cohort: “HSCC is often undetected until advanced stages” and “More than 50% of patients … present at an advanced stage” (katano2024earlystagehypopharyngealsquamous pages 1-2).

8.2 Staging system

Staging follows AJCC TNM for hypopharyngeal SCC, with T descriptors incorporating extension/subsite involvement and invasion of structures including the cricoid cartilage (T4a) (sahu2023imagingrecommendationsfor pages 10-12).

9. Inheritance and population

9.1 Epidemiology (prioritizing 2024)

A 2024 GLOBOCAN 2020 analysis reported: * 84,254 new cases globally in 2020; ASIR 0.91 per 100,000. * 38,599 deaths in 2020; ASMR 0.41 per 100,000. * MIR 0.45. * Projected increases by 2040: +50% new cases and +55% deaths (mousavi2024globalepidemiologyand pages 1-2).

Subsite distribution of hypopharyngeal cancer reported in the same source: ~70% pyriform sinus, ~25% posterior pharyngeal wall, remainder largely post-cricoid (mousavi2024globalepidemiologyand pages 1-2).

9.2 Sex and age distribution

Hypopharyngeal cancer shows higher incidence/mortality in men than women and increases with age (notably ≥70 years) (mousavi2024globalepidemiologyand pages 1-2, mousavi2024globalepidemiologyand pages 2-3).

10. Diagnostics

10.1 Clinical tests and imaging (guideline-style synthesis)

Imaging recommendations emphasize that endoscopy is essential for mucosal assessment but is insufficient for complete staging because submucosal and deep-space spread can be missed.

NCCN-referenced diagnostic workup items (as quoted/compiled in Sahu 2023): * “examination under anesthesia with endoscopy” * “CECT and/ or MRI for primary and neck” * “Chest CT … for advanced nodal disease” * “FDG PET-CT … for stage III-IV disease” (sahu2023imagingrecommendationsfor pages 1-2)

Postcricoid-specific imaging note: post-cricoid hypopharyngeal carcinoma is described as uncommon and “often shows submucosal spread toward the cervical esophagus,” with MRI better delineating extent (sahu2023imagingrecommendationsfor pages 5-8).

10.2 Histopathology

Squamous cell carcinoma is the predominant histology in hypopharyngeal cancer (mousavi2024globalepidemiologyand pages 1-2, li2026novellaryngealpreservation pages 1-2).

10.3 Biomarkers (current practice direction)

PD-1/PD-L1 axis is clinically actionable in HNSCC broadly and is integral to the modern immunotherapy-based organ-preservation strategies tested in hypopharyngeal cancer trials (NCT04156698 chunk 1, NCT06039631 chunk 1).

10.4 Differential diagnosis

Sahu 2023 notes non-squamous malignant lesions are rare and often submucosal; a full differential diagnosis list was not extracted in the current evidence set (sahu2023imagingrecommendationsfor pages 1-2).

11. Outcome / prognosis

11.1 Survival statistics from recent/authoritative studies

  • Early-stage hypopharyngeal SCC treated with definitive RT (70 Gy/35 fractions) reported 5-year OS 80.7%, and for the postcricoid subsite 5-year OS 100% in a small subsite-stratified subset (katano2024earlystagehypopharyngealsquamous pages 1-2).
  • For hypopharyngeal carcinoma treatment modality comparisons (retrospective): 5-year OS 59.7% (surgery-based therapy) vs 24.0% (definitive chemoradiotherapy) (p<0.0001), and 5-year PFS 49.9% vs 22.6% (p=0.0002) (lin2023survivalanalysesof pages 1-2).

11.2 Prognostic factors

Performance status (ECOG PS) was an independent OS risk factor in the early-stage RT cohort (HR 8.457) (katano2024earlystagehypopharyngealsquamous pages 1-2).

12. Treatment

12.1 Standard modalities (real-world implementation)

Early stage: single-modality RT or surgery; a uniform definitive RT approach of 70 Gy/35 fractions with elective nodal irradiation is feasible with low high-grade toxicity in one modern series (katano2024earlystagehypopharyngealsquamous pages 1-2).

Advanced disease: multimodality management. Imaging recommendations summarize: “Early stage disease is treated with single modalities such as radiotherapy or surgery. Advanced disease is treated with multimodality of either chemoradiotherapy or surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy.” (sahu2023imagingrecommendationsfor pages 1-2).

12.2 Surgery vs definitive CRT

A retrospective cohort comparing surgery-based therapy (SBT) vs definitive chemoradiotherapy (CRT) found significantly better survival with SBT overall; however, for some subgroups (e.g., T3/stage III) survival differences were less pronounced (lin2023survivalanalysesof pages 1-2).

12.3 Immunotherapy and organ-preservation developments (prioritizing 2023–2024)

Key 2024 phase II trial (directly in hypopharyngeal SCC): * Nature Communications 2024 reports: “This phase II trial aimed to determine the efficacy and safety of induction chemoimmunotherapy of camrelizumab plus modified TPF in locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) (NCT04156698).” It reports ORR 82.4% and interim 2-year OS/PFS/LPR outcomes: 2-year OS 83.0%, PFS 77.1%, larynx preservation rate 70.0% (sahu2023imagingrecommendationsfor media ea5671f7, NCT04156698 chunk 1).

Ongoing 2023-start randomized phase II organ-preservation strategy (larynx/hypopharynx): * NCT06039631 (Fudan University; recruiting; start Aug 22, 2023) randomizes post-neoadjuvant chemoimmunotherapy patients to organ-preservation surgery vs concurrent chemoradiation (RT 70 Gy/35 fractions plus weekly cisplatin in one arm), with adjuvant toripalimab; primary endpoint is 2-year PFS and key secondary endpoints include larynx preservation rate and QoL (MDADI, VHI-10) (NCT06039631 chunk 1).

12.4 Suggested MAXO terms (examples)

(MAXO IDs are suggested; the retrieved sources do not contain explicit MAXO mappings.)

13. Prevention

13.1 Primary prevention

Risk-factor modification (tobacco/alcohol reduction) is implied by the strong risk-factor association described in clinical guidance (sahu2023imagingrecommendationsfor pages 1-2).

13.2 Secondary prevention (high-risk surveillance)

Plummer–Vinson syndrome is consistently described as carrying malignancy risk that warrants surveillance: * PVS review abstract: “the risk of malignancy warrants long-term surveillance” (lo2019plummervinsonsyndromeimproving pages 1-2). * A PVS-focused excerpt notes “Surveillance endoscopy can be performed yearly, though no definitive recommendation exists” (patil2023endoscopicsubmucosaldissection pages 2-4).

14. Other species / natural disease

No naturally occurring postcricoid-region cancer analogs in other species were identified in the retrieved evidence set.

15. Model organisms

No postcricoid-region–specific experimental animal models were identified in the retrieved evidence set; mechanistic studies are therefore typically extrapolated from broader HNSCC models (cell lines, xenografts/PDX), but this is a current evidence gap in this retrieval (afshari2023potentialalternativetherapeutic pages 1-2).

Notes on evidence gaps and limitations

  • Postcricoid-region–specific molecular profiling, differential diagnosis, and model organism literature were not retrieved at depth in this run; much of the molecular discussion necessarily relies on broader HNSCC/HSCC evidence (afshari2023potentialalternativetherapeutic pages 1-2, shirima2024epithelial‑derivedheadand pages 3-4).
  • Several modern immunotherapy studies relevant to hypopharyngeal SCC exist beyond 2024; however, the highest-priority 2023–2024 organ-preservation chemoimmunotherapy trial evidence in this set is NCT04156698 / Nature Communications 2024 (NCT04156698 chunk 1).

Key URLs (as retrieved)

References

  1. (glastonbury2020headandneck pages 1-2): Christine M. Glastonbury. Head and neck squamous cell cancer: approach to staging and surveillance. IDKD Springer Series, pages 215-222, Feb 2020. URL: https://doi.org/10.1007/978-3-030-38490-6_17, doi:10.1007/978-3-030-38490-6_17. This article has 46 citations.

  2. (mousavi2024globalepidemiologyand pages 1-2): Seyed Ehsan Mousavi, Mehran Ilaghi, Yasaman Mirzazadeh, Alireza Mosavi Jarrahi, and Seyed Aria Nejadghaderi. Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from globocan 2020. Frontiers in Oncology, Sep 2024. URL: https://doi.org/10.3389/fonc.2024.1398063, doi:10.3389/fonc.2024.1398063. This article has 13 citations.

  3. (sahu2023imagingrecommendationsfor pages 5-8): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  4. (katano2024earlystagehypopharyngealsquamous pages 1-2): Atsuto Katano and Hideomi Yamashita. Early-stage hypopharyngeal squamous cell carcinoma treated with radical radiotherapy at a uniform dose of 70 gy in 35 fractions: a single-center study. European Archives of Oto-Rhino-Laryngology, 281:4401-4407, May 2024. URL: https://doi.org/10.1007/s00405-024-08722-w, doi:10.1007/s00405-024-08722-w. This article has 11 citations and is from a peer-reviewed journal.

  5. (mousavi2024globalepidemiologyand pages 2-3): Seyed Ehsan Mousavi, Mehran Ilaghi, Yasaman Mirzazadeh, Alireza Mosavi Jarrahi, and Seyed Aria Nejadghaderi. Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from globocan 2020. Frontiers in Oncology, Sep 2024. URL: https://doi.org/10.3389/fonc.2024.1398063, doi:10.3389/fonc.2024.1398063. This article has 13 citations.

  6. (sahu2023imagingrecommendationsfor pages 1-2): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  7. (sahu2023imagingrecommendationsfor pages 2-3): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  8. (katano2024earlystagehypopharyngealsquamous pages 2-5): Atsuto Katano and Hideomi Yamashita. Early-stage hypopharyngeal squamous cell carcinoma treated with radical radiotherapy at a uniform dose of 70 gy in 35 fractions: a single-center study. European Archives of Oto-Rhino-Laryngology, 281:4401-4407, May 2024. URL: https://doi.org/10.1007/s00405-024-08722-w, doi:10.1007/s00405-024-08722-w. This article has 11 citations and is from a peer-reviewed journal.

  9. (lin2023survivalanalysesof pages 1-2): Tian-Yun Lin, Tsung-Lun Lee, Yen-Bin Hsu, Shyh-Kuan Tai, Ling-Wei Wang, Muh-Hwa Yang, and Pen-Yuan Chu. Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1109417, doi:10.3389/fonc.2023.1109417. This article has 10 citations.

  10. (lin2023survivalanalysesof pages 2-3): Tian-Yun Lin, Tsung-Lun Lee, Yen-Bin Hsu, Shyh-Kuan Tai, Ling-Wei Wang, Muh-Hwa Yang, and Pen-Yuan Chu. Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1109417, doi:10.3389/fonc.2023.1109417. This article has 10 citations.

  11. (patil2023endoscopicsubmucosaldissection pages 1-2): Gaurav Patil, Amol Vadgaonkar, Ankit Dalal, Sanil Parekh, Animesh Shah, Poorva Haridas, Prajakta Gupte, Sehajad Vora, and Amit Maydeo. Endoscopic submucosal dissection for esophageal squamous cell high-grade dysplasia in a patient with plummer vinson syndrome. Journal of Digestive Endoscopy, 14:051-055, Dec 2023. URL: https://doi.org/10.1055/s-0042-1759510, doi:10.1055/s-0042-1759510. This article has 1 citations.

  12. (lo2019plummervinsonsyndromeimproving pages 5-6): Kevin Bryan Lo, Jeri Albano, Naemat Sandhu, and Nellowe Candelario. Plummer-vinson syndrome: improving outcomes with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12:471-477, Jun 2019. URL: https://doi.org/10.2147/jmdh.s180410, doi:10.2147/jmdh.s180410. This article has 35 citations and is from a peer-reviewed journal.

  13. (patil2023endoscopicsubmucosaldissection pages 2-4): Gaurav Patil, Amol Vadgaonkar, Ankit Dalal, Sanil Parekh, Animesh Shah, Poorva Haridas, Prajakta Gupte, Sehajad Vora, and Amit Maydeo. Endoscopic submucosal dissection for esophageal squamous cell high-grade dysplasia in a patient with plummer vinson syndrome. Journal of Digestive Endoscopy, 14:051-055, Dec 2023. URL: https://doi.org/10.1055/s-0042-1759510, doi:10.1055/s-0042-1759510. This article has 1 citations.

  14. (lo2019plummervinsonsyndromeimproving pages 2-3): Kevin Bryan Lo, Jeri Albano, Naemat Sandhu, and Nellowe Candelario. Plummer-vinson syndrome: improving outcomes with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12:471-477, Jun 2019. URL: https://doi.org/10.2147/jmdh.s180410, doi:10.2147/jmdh.s180410. This article has 35 citations and is from a peer-reviewed journal.

  15. (NCT04156698 chunk 1): Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma. Eye & ENT Hospital of Fudan University. 2020. ClinicalTrials.gov Identifier: NCT04156698

  16. (NCT06039631 chunk 1): Yu Wang. Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer. Fudan University. 2023. ClinicalTrials.gov Identifier: NCT06039631

  17. (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma): Open Targets Query (hypopharyngeal carcinoma,head and neck squamous cell carcinoma, 13 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  18. (li2026novellaryngealpreservation pages 1-2): Xuexin Li, Xiaoran Zhang, Yun Lin, Yan Ma, Zheng Jiang, Dapeng Lei, Xinliang Pan, and Jun Liu. Novel laryngeal preservation technique in postcricoid hypopharyngeal carcinoma: a case-series study. BMC Surgery, Mar 2026. URL: https://doi.org/10.1186/s12893-026-03586-9, doi:10.1186/s12893-026-03586-9. This article has 0 citations and is from a peer-reviewed journal.

  19. (lo2019plummervinsonsyndromeimproving pages 1-2): Kevin Bryan Lo, Jeri Albano, Naemat Sandhu, and Nellowe Candelario. Plummer-vinson syndrome: improving outcomes with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12:471-477, Jun 2019. URL: https://doi.org/10.2147/jmdh.s180410, doi:10.2147/jmdh.s180410. This article has 35 citations and is from a peer-reviewed journal.

  20. (NCT06957938 chunk 2): Yu Wang. Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma. Fudan University. 2025. ClinicalTrials.gov Identifier: NCT06957938

  21. (shirima2024epithelial‑derivedheadand pages 3-4): Charles Shirima, Coralia Bleotu, Demetrios Spandidos, Adel El‑Naggar, Gratiela Gradisteanu Pircalabioru, and Ioannis Michalopoulos. Epithelial‑derived head and neck squamous tumourigenesis (review). Oncology Reports, Aug 2024. URL: https://doi.org/10.3892/or.2024.8800, doi:10.3892/or.2024.8800. This article has 12 citations and is from a peer-reviewed journal.

  22. (afshari2023potentialalternativetherapeutic pages 1-2): Keihan Afshari and Karpal Singh Sohal. Potential alternative therapeutic modalities for management head and neck squamous cell carcinoma: a review. Cancer Control : Journal of the Moffitt Cancer Center, Apr 2023. URL: https://doi.org/10.1177/10732748231185003, doi:10.1177/10732748231185003. This article has 13 citations.

  23. (sahu2023imagingrecommendationsfor media 624946c3): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  24. (sahu2023imagingrecommendationsfor media dd0e55cc): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  25. (sahu2023imagingrecommendationsfor media 9d694104): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  26. (sahu2023imagingrecommendationsfor media 0adf3cdb): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  27. (sahu2023imagingrecommendationsfor media ea5671f7): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  28. (sahu2023imagingrecommendationsfor media 2fc9a3ce): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  29. (sahu2023imagingrecommendationsfor pages 10-12): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.